Pretax income is the income that a company earns before paying income taxes. Ensysce Biosciences's pretax income for the
three
months ended in Mar. 2024 was $-3.12 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.55 Mil.
Ensysce Biosciences's pretax margin was %.
Ensysce Biosciences Pre-Tax Income Historical Data
The historical data trend for Ensysce Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ensysce Biosciences's Pre-Tax Income
For the Biotechnology subindustry, Ensysce Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's Pre-Tax Income falls into.
Ensysce Biosciences Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Ensysce Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ensysce Biosciences (NAS:ENSC) Pre-Tax Income Explanation
Ensysce Biosciences's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ensysce Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Ensysce Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensysce Biosciences (Ensysce Biosciences) Business Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENSC has been successfully added to your 